Moneycontrol
HomeNewscoronavirus3-Point Analysis | Why is Bharat Biotech’s ‘Covaxin’ receiving backlash post approval?

3-Point Analysis | Why is Bharat Biotech’s ‘Covaxin’ receiving backlash post approval?

The Drug Controller General of India (DCGI) on January 3 granted permission for restricted emergency use of the AstraZeneca-Oxford University and Bharat Biotech Covid-19 vaccines. The approval was based on the recommendations of the Subject Expert Committee (SEC), which reviewed the data on safety and immunogenicity of the two vaccines. However, post the announcement it is India’s indigenous vaccine which has found itself in the middle of a controversy. Here’s why.

Moneycontrol News
January 04, 2021 / 18:46 IST
Story continues below Advertisement
Remove Ad

Moneycontrol News
TAGS: #coronavirus #video
first published: Jan 4, 2021 06:46 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
Trending Topics
Sensex Today GST Cut on Cars Amazon H1B News CPEC News EPF Withdrawal Rules Gold Price UAE Visa Ban Katrina Kaif Pregnancy Kolkata Rains Volvo EX30 Price in India
News
Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups
Markets
Home Currencies Commodities Pre-Market IPO Global Market Bonds
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker New Fixed Deposits Fixed Deposit Comparison Fixed Income
Mutual Funds
Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener
Tools
Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator Petrol Price in India Diesel Price in India IFSC Code
Community
Stock Markets
Network 18 Sites
News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive
Quick Links
About Us Contact Us Advisory Alert Advertise with Us Disclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.